肥胖与不同病因慢性肝病进展及严重程度相关性

努尔 阿米, 艾克 丹木
新疆医科大学第二附属医院 新疆乌鲁木齐 83000

摘要

摘要：肝硬化(HC)是不同病因的慢性肝病持续进展的共同结局，肝硬化失代偿期合并症多，死亡率高。积极控制加重肝硬化失代偿期病情进展的危险因素，对减少并症发生率，改善患者预后有重要意义。肥胖已被证实为是多种慢性疾病的危险因素，随着肥胖患病率增加，越来越多慢性肝病患者合并肥胖。本综述中，介绍了肥胖与不同病因慢性肝脏疾病严重程度与预后相关性的研究进展。

关键词

关键词：肥胖；慢性肝病；肝硬化；肝癌

参考

[1]Engin A.The Pathogenesis of Obesity-Associated AdiposeTissueInflammation. Adv Exp Med Biol,2017 , 960:221-245.[2]Ahn JC, Sundaram V. Obesity and Liver Decompensation. Clin LiverDis ( Hoboken) ,201914:12-15.[3]Hagstrom H，Stal P，Hultcrantz R，et al.Overweight in late adolescencepredicts development of severe liver disease later in life：A 39 years follow-upstudy[J].JHepatol，2016，65（2）：363-368.[4]Sohn W ,LeeHW, Lees,etal. Obesity and the risk of primarylivercancer: A systematic review and meta analysis [J] . Clin Mol Hepatol,2021, 27 (1):157-174.[5]Kim Y,Chang Y,Cho YK,et al. Obesity and Weight Gain AreAs-sociated With Progression of Fibrosis in Patients With NonalcoholicFattyLiverDisease[J]. Clin Gastroenterol Hepatol, 2019,17(3):543 -550. e2.[6]Leung JC, Loong TC, Wei JL, et al. Histological severity and clinicaloutcomes of nonalcoholie fatty liver disease in nonobese patients[J].Hepatology,2017 ,65(1) :54-64.[7]Patel YA ,Gifford EJ,Glass LM,et al.Risk factors for biopsy-provenadvanced non-alcoholie fatty liver disease in the Veterans Health AdministrationIJ 1 Aliment Pharmacol Ther, 2018.47(2):268-278.[1]Jarvis, Helen et al. Metabolic risk factors and incident advancedliverdisease in non-alcoholic fatty liver disease (NAFLD): A systematic reviewand meta-analysis of population-based observational studies.PLoS me dicinevol. 17,4 e1003100. 30 Apr. 2020。[2]Fan Rong,Niu Junqi,Ma Hong et al. Association of central obesitywithhepatocellular carcinoma in patients with chronic hepatitis Breceivinganti-viral therapy.[J] .Aliment Pharmacol Ther, 2021, 54: 329-338.[3]吴琦琦,马燕,王晓波,等. 代谢综合征对慢性乙型肝炎患者显著肝纤维化的影响[J]. 临床肝胆病杂志,2018,34(12):2572-2577.[4]Jacobson I M, Washington M K, Buti M, et al. FactorsAssociatedWithPersistent Increase in Level of Alanine Aminotransferase in PatientsWithChronic Hepatitis B Receiving Oral Antiviral Therapy[J].ClinicalGastroenterology and Hepatology,201 7,15(7):1087-94.[5]Mak L-Y, Hui R-H, Fung J, et al.Diverse effects of hepatic steatosison fibrosis progression and functional cure in virologically quiescent chronichepatitis B. J Hepatol. 2020;73:800-806.[6]莫瑞东,章正兰,殷荣坤,等. 肥胖对 HBV 相关慢加急性肝衰竭和失代偿性肝硬化患者疾病严重程度和短期预后的影响[J]. 肝脏,2022,27(7):742-747,755.[7]LEE Y B, HA Y,CHONYE, et al. Association between hepaticsteatosisand the development of hepatocellular carcinoma in patientswith chronichepatitis B[J]. Clin Mol Hepatol,2019,25(1):52-64.[8]孔钦香,董金玲. 慢性丙型肝炎合并脂肪肝的临床特征及危险因素分析[J].中国基层医药,2022,29(10):1495-1500.[9]张 妮 娜. 丙 型 肝 炎 后 肝 硬 化 影响 因 素 分 析[J]. 中 国 实 用 医刊,2018,45(5):33-38[10]周莉,郭洁,刘钰佩,等. 慢性丙型肝炎病毒感染患者获得持续病毒学应答后肝细胞癌发生的危险因素[J]. 中华传染病杂志,2022,40(10):607-612.[11]MEHTA M, SATSANGI s, DUSEJA A, et al. Can alcoholic liverdisease and nonalcoholic fatty liver disease co-exist[J].J Clin Exp Hepatol,2017, 7 (2):121-126.[12]BAECKER A. LIU x. L A VECCHIAC. et al.Worldwide incidence ofhepatocellular carcinoma cases attribulable to maior risk factors[J]. Eur JCancer Prev, 2018. 27(3):205-212.[13]SAHLMAN P. NISSINEN M, PUUKKAP, et al. Genetic and lifestylerisk factors for advancedliver disease amongmen andwomen[J]. J GastroenterolHepatol, 2020,35(2):291-298.[14]Duseja A, De A, TanejaS,etal.Impact of metabolic riskfactors on theseveriy and outcome of patients with alcohol associated acute on-chronic liverfailure.Liver Int, 2021, 41 :150-157.